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Identification of wild-type and mutant p53 
peptides binding to HLA-A2 assessed by a 
peptide loading-deficient cell line assay and a 
novel major histocompatibility complex class I 
peptide binding assay* 
Mutations of the p53 gene are the most frequently observed genetic changes in 
human cancers; often leading to an overexpression of the wild-type (wt) p53 
protein. Demonstrable T cell reactivity against tumor cells overexpressing wt or 
mutant p53-derived peptides could support the application of such epitopes in 
cancer immunotherapies. As the binding of peptide to MHC class I molecules is a 
prerequisite for antigen-specific T cell recognition, we evaluated the ability of wt 
and mutant p53 peptides to bind to HLA-A2.1 using two independent flow 
cytometry-based assay systems, the T2 major histocompatibility complex (MHC) 
class I peptide stabilization assay (stabilization assay) and the peptide-induced 
MHC class I reconstitution assay (reconstitution assay). The twenty selected wt 
sequences each conformed to the previously reported HLA-A2.1 peptide binding 
motif. Seven of the wt p53 and 2/13 mutant p53 peptides derived from the 
previously chosen wt peptides bound to HLA-A2.1 in both the stabilization and 
the reconstitution assays. An additional six wt and six mutant p53 peptides, 
presumably exhibiting lower affinity for HLA-A2.1, were identified only in the 
reconstitution assay. Those p53 peptides binding HLA-A2.1 may provide useful 
immunogens for the generation of HLA-A2. l-restricted cytolytic T lymphocytes 
in vitro and in vivo. 
1 Introduction 
Mutations or deletions of the p53 gene are the most 
commonly observed changes associated with human can- 
cers [l, 21. Mutated p53 protein may complex with, and 
stabilize, wt p53 resulting in overexpression and a pro- 
longed tl/z of the complex in tumor cells [3, 41. This 
resultant overexpression of p53 protein can be visualized 
immunohistochemically [5].  Such p53 overexpression may 
also serve to provide peptide epitopes, presented by tumor 
cell MHC molecules, in sufficient quantities to elicit 
humoral and cellular (i.e. T cell) immune responses in 
cancer patients [6,7]. Mutant or wt p53 peptides presented 
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Major histocompatibility complex class I 
by MHC class I molecules could stimulate anti-tumor 
CDW CTL responses, potentially beneficial in the design 
of cancer immunotherapy. In this report, we studied a panel 
of wt and mutant p53 peptides for their capacity to bind to 
the HLA-A2.1 molecule using two independent flow 
cytometry-based assay systems: theT2 MHC class I peptide 
stabilization assay (stabilization assay) [8] and the peptide- 
induced MHC class I reconstitution assay (reconstitution 
assay) [9]. 
2 Materials and methods 
2.1 Cell lines 
The peptide presenting defective T2 (T (CEM) x B (.174) 
hybrid) cell line [lo] (kindly provided by Dr. €? Cresswell, 
Howard Hughes Medical Institute, Immunobiology Sec- 
tion,Yale University School of Medicine, New Haven, CT) 
and the human ClR.A2.1 B-cell line [ l l ]  were grown in 
RPMI1640 medium supplemented with 2 mM L-glutamine, 
10 % heat-inactivated FCS, 100 U/ml penicillin, and 
100 yg/ml streptomycin. Hepes (0.1 mM) was also added to 
T2 cultures. All culture reagents were from Gibco (Grand 
Island, NY). 
2.2 Peptides 
Twenty wt p53 peptides conforming to the HLA-A2.1 
binding motif [12] were selected using a peptide mapping 
program ([13], Table 1). Peptides were synthesized as 
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Table 1. p53 wild-type and mutant peptides 
Name (amino acids) Source Sequence (position) 
1 2 3 4 5 6 7 8 9  
p53 24-32 UVR K L L P E N N V L  
p53 42-50 PC I D L M L S P D D I  
p53 43-52 UVR L M L S P D D I E Q  
p53 65-73 UVR/PCI R M P E A A P P V  
p53 92-100 PCI P L S S S V P S Q  
p53 110-118 PCI R L G F L H S G T  
p53 129-137 WR/PCI A L N K M F C Q L  
p53 132-140 UVR K M F C Q L A K T  
p53 132 M1 UVR Q M F C Q L A K T  
p53 136-144 WR Q L A K T C P V Q  
p53 159-167 
p53 159 M1 
p53 186-196 
p53 187-195 
p53 187 M1 
p53 193-201 
p53 193 M1 
p53 193 M2 
p53 193 M3 
p53 193 M4 
D53 245-253 
p53 245 M1 
p53 245 M2 
D53 245 M3 
p 5 3  245 M4 
p53 250-258 
p53 256-265 
p53 263-272 
p53 264-272 
p53 264 Ml 
p53 264 MZ 
p53 322-330 
p53 331-339 
UVR 
UVR 
PCI 
WR 
UVR 
WR/PCI 
m 
WR 
W R  
UVR 
W R  
WR 
UVR 
UVR 
UVR 
WR 
UvR/PCI 
UVR 
PCI 
UVR 
W R  
m / p c r  
UVR 
A M A I Y K Q S Q  
A M A I B K Q S Q  
D G L A P P Q H L I R  
G L A P P Q H L I  
G L A P P Q H E I  
H L I R V E G N L  
R L I R V E G N L  - 
H L I K V E G N L  
E L I R V E G N L  
H B I R V E G N L  
G M N R R P I L T  
G M N C R P I L T  
G M N K R P I L T  
G M N E R P I L T  
G M N R K P I L T  
P I L T I I T L E  
T L E D S S G N L L  
N L L G R N S F E V  
L L G R N S F E V  
L L G R N S F E U  
L L G R N S E E W  
P L D G E Y F T L  
Q I R G R E R F E  
Co., St. Louis, MO) was diluted in PBS (100pM) and 
aliquots stored at - 20°C prior to use. 
2.3 Stabilization assay 
The assay was performed as previously described IS]. 
Briefly, T2 cells (2.5 X lo5) were incubated with 100 pM 
peptides for 24 h at 37”C, or for increased sensitivity at 
26°C in AIM V medium. Cells were then stained for 
HLA-A2 by indirect immunofluorescence using mAB 
BB7.2 (anti-mA-A2, American Type Culture Collection, 
Rockville, MD) and FITC-labeled (1 : 20) rabbit anti- 
mouse antibodies (Sigma). Results were determined on a 
FACS sorter (FACS IV, Becton Dickinson, Mountainview, 
CA) and expressed as x-fold increase in fluorescence 
intensity (FI): FI sample/FI control (cells without pep- 
tide). 
2.4 Reconstitution assay 
The assay was performed as previously described [91. 
Briefly, C1R.A2.1 cells were treated for 1 min with pH 3.2 
citrate-phosphate buffer to denature class I complexes. 
After neutralization with excess AIM-V medium (Gibco), 
cells (> 92 YO viable) were incubated in 100 nM hPz-m, 2 pg 
mAb BB7.2, and either no peptide (negative control) or 
10 pM peptide for 4 h at room temperature (total sample 
volume = 200 yl). After washing with AIM-V media, 2 yl 
of FITC-conjugated goat anti-mouse IgG F(ab’)z was 
added to cell pellets for 30 min at 4°C. Results were 
determined as noted above for the stabilization assay. 
9-mers or, for increased solubility as 10- or 11-mers, by the 
Peptide Synthesis Facility (Shared Resource, Pittsburgh 
Cancer Institute) or as previously described [14]. Thirteen 
additional peptides containing natural point mutations 
observed in the p53 gene were also synthesized. HPLC- 
purified peptides were dissolved in PBS (1 mM) just prior to 
use. Human P2-microglobulin (hP2-m; Sigma Chemical 
3 Results 
3.1 wt (7/19) and mutant (2/13) p53 peptides bind 
HLA-A2.1 in the stabilization assay 
As depicted in Fig. 1,7/19 wt and 2/13 mutant p53 peptides 
induced a greater than 1.4-fold increase in HLA-A2.1 
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Peptide Examined: 
Figure 1. HLA-A2 binding ca- 
pacity of wt and mutant p53 
peptides assessed by the MHC 
class I stabilization assay at 
26 “C. The standard deviations 
of the individual tests are calcu- 
lated from the FI values of ten 
control samples. The Fig. sum- 
marizes the cumulative result of 
five assays. Flu M1 58-66 is an 
HLA-A2.1 binding peptide 
used as control. 
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Figure 2. HLA-A2 binding ca- 
pacity of wt p53 peptides 
Peptide Examined: peptides from four assays. 
expression byT2 after 24 h of co-incubation at 26 "C. One of 
the wt (p53 322-330) and both of the mutant p53 peptides 
did not stabilize HLA-A2.1 on T2 when incubations were 
carried out at 37 "C, suggesting that these peptide-class I 
interactions are of somewhat lower affinity than those 
involving p53 peptides stabilizing HLA-A2.1 at both 
temperatures [15]. The sensitivity of the stabilization assay 
was enhanced at the reduced (26%) temperature, a 
phenomenon similarly noted in the binding of peptides to 
RMA-S cells [15]. A minimum of 1-10nM peptide was 
required for stabilization; lower doses were insufficient, as 
also seen with the known CTL epitope influenza matrix 
58-66 (Flu M1 58-66) [16]. 
3.2 wt (13120) and mutant (8113) p53 peptides bind 
HLA-A2.1 in the reconstitution assay 
As shown in Fig. 2, 13/20 wt and 8/13 mutant p53 peptides 
significantly (1.8-6.4-fold control values) reconstituted 
HLA-A2.1 complexes on the ClR.A2.1 cell line in the 
presence of hp2-m. Each of the p53 peptides determined to 
bind HLA-A2.1 in the stabilization assay were shown to 
bind HLA-A2.1 in the reconstitution assay. Six additional 
wt and six additional mutant p53 peptides were deduced to 
bind HLA-A2.1 only in the reconstitution assay. 
4 Discussion 
The high frequency of p53 mutations and wt p53 protein 
overexpression in human tumors vs. normal tissue makes 
p53 a potential candidate tumor rejection antigen. The 
documentation of humoral IgG immune responses directed 
against p53 in cancer patients supports the idea of cellular 
(i.e. CD4+ Th-cell) immune recognition of p53 peptide 
epitopes [6,7].We and others hypothesize that CD8+ T cell 
reactivity to p53 sequences might also be naturally gener- 
ated in cancer patients, and that suchT cell reactivity would 
be directed against short eight to ten-amino acid peptides 
presented by MHC class I molecules [17, 181. We have 
identified a series of p53 peptides, conforming to the 
previously reported HLA-A2.1 binding motif [ 121, that 
bind to the HLA-A2.1 class I molecule using two indepen- 
dent flow cytometry-based assays. Recently, each of these 
assay systems has been demonstrated in titration experi- 
ments to have a detection limit of approximately 1-10 nM 
peptide for the binding of the CTL epitope influenza matrix 
58-66 to HLA-A2.1 [16]. The effective concentration of 
peptide and catalytic mechanisms at the site of peptide 
loading are not known, and it is therefore difficult to 
speculate about the physiological implications of the pep- 
tide concentrations used in the assays. We note, however, 
that the lower detection limit for several of the positive 
peptides in this study is in the same range as the one 
observed for several known CTL epitopes in similar assays 
([8, 15, 161, unpublished observations). Each assay system 
is capable of clearly discerning low vs. high affinity 
class I-binding peptides [16], with the stabilization (26°C) 
assay displaying a higher degree of sensitivity than the 
stabilization (37 "C) assay [15]. Both assay systems support 
the strong binding of six wt p53 peptides (p53 65-73, p53 
322-330) and somewhat lower affinity binding of wt p53 
24-32 to HLA-A2.1. In contrast to the stabilization assay, 
the reconstitution assay suggested the additional strong 
binding of wt p53 43-52 and p53 136-144 and the interme- 
diatellow affinity binding of p53 186-196, p53 193-201, p53 
245-253, and p53 256-265 to HLA-A2.1. The binding 
analysis of mutant p53 peptides suggests: (1) no mutant p53 
peptide bound to HLA-A2.1 with an apparent higher 
affinity than its wt p53 analog, (2) the 9-mer p53 187-195 
bound far better than the 11-mer p53 186-196, emphasizing 
the critical importance of peptide length in binding to 
class I molecules [19,20], and (3) several mutations 
appeared to inhibit p53 peptide binding to HLA-A2.1. In 
particular, the substitution of position 1 H-> R or H-> E in 
p53 193M1 and p53 193M3, respectively, ablates peptide 
binding to HLA-A2.1. In  addition, as expected, substitu- 
tion of the position 2 "anchor" L-> E in p53 193M4 also 
ablated binding. Further, while a V-> M mutation (p53 
264M1) at position 9 was tolerated by the HLA-A2.1 
binder p53 264-272, the additional F-> E mutation at 
position 7 (p53 264M2) substantially reduced the binding 
129-137, p53 187-195, p53 263-272, p53 264-272, p53 
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capacity of the peptide. Minor changes in HLA-A2.1 
binding capacity resulted from amino acid substitutions at 
wt p53 peptide positions 415 (p53 186M1, p53 193M2, p53 
245Ml-M4), which according to the Rammensee motif [12] 
are predicted to be less involved in MHC class I-peptide 
interactions. These positions are predicted to influence 
T cell receptor contact with class I-peptide complexes, and 
would be anticipated to result in potential - neo p53 T-cell 
epitopes. 
In conclusion, this study has identified a series of p53- 
derived peptides capable of binding to HLA-A2.1 using 
two independent assay systems. We do not know whether 
any of these sequences is naturally processed and presented 
by HLA-A2.1 on HLA-A2.1f tumor cells, and if so, 
whether they can be recognized as T cell epitopes. Nev- 
ertheless, these results provide a panel of potential T cell 
epitopes that may now be evaluated for their immunoge- 
nicity in vitro. 
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